William E. Rote, Chief Research Officer at Travere Therapeutics, Inc. (TVTX), sold 2,763 shares at $43.95 ($121K) on 2026-05-06, disclosed to the SEC on 2026-05-06.
Scheduled sale ($121k) by Chief Research Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TVTX | SELL | 2026-02-03 | $409K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $2.4M | — | Filing → |
| TVTX | SELL | 2025-05-05 | $135K | — | Filing → |